KAELYN LAY: Open Payments
NPI 1962948075 · NORTH LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,429 in 75 payments from 18 companies in 2025. Trend: 2023 $824 · 2024 $1,826 · 2025 $1,429
Food & beverage: $1,429
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $319 |
| ABBVIE INC. | 11 | $267 |
| Lilly USA, LLC | 14 | $209 |
| PFIZER INC. | 6 | $105 |
| Astellas Pharma US Inc | 4 | $78 |
| Amgen Inc. | 5 | $72 |
| Novo Nordisk Inc | 4 | $67 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
Products named: FARXIGA, QULIPTA, MOUNJARO, JARDIANCE, AIRSUPRA, Veozah, UBRELVY, OTEZLA.
Industry payments across AR — which companies pay providers there.
